Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pain Therapeutics (PTIE) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 27,700
  • Shares Outstanding, K 46,140
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,150 K
  • 36-Month Beta 2.19
  • Price/Sales N/A
  • Price/Book 1.36
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.75 on 12/13/12
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.57 +1.79%
on 01/03/17
0.73 -20.52%
on 12/22/16
-0.04 (-6.42%)
since 12/16/16
3-Month
0.51 +13.76%
on 11/04/16
0.84 -30.93%
on 11/22/16
-0.07 (-10.74%)
since 10/18/16
52-Week
0.51 +13.76%
on 11/04/16
3.00 -80.66%
on 09/20/16
-1.08 (-65.05%)
since 01/15/16

Most Recent Stories

More News
Pain Therapeutics to Discuss REMOXY(R) ER with FDA

Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced it plans to meet with the U.S. Food and Drug Administration (FDA) in person on Monday, February 13, 2017 to discuss the regulatory path forward for...

Global Pain Therapeutics Drugs, Markets and Companies report 2015-2025: Epidemiology of Various Painful Conditions and the Development of Analgesic Drugs and Devices

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.

Research Reports Initiation on Biotech Stocks -- Pacific Biosciences of California, Aralez Pharma, Cerus, and Pain Therapeutics

Stock-Callers.com has issued research reports on four Biotech equities, which are Pacific Biosciences of California Inc. (NASDAQ: PACB), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), Cerus Corp. (NASDAQ:...

Research Reports Initiation on Biotech Stocks -- Spectrum Pharma, Pain Therapeutics, CoLucid Pharma, and CEL-SCI

Stock-Callers.com has initiated coverage on the following Biotechnology companies: Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Pain Therapeutics Inc. (NASDAQ: PTIE), CoLucid Pharmaceuticals Inc. (NASDAQ:...

Pain Therapeutics Reports Q3 2016 Financial Results

Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the third quarter of 2016. Net loss in Q3 2016 was $3.5 million, or $0.08 per share, compared to a net loss in Q3 2015 of $3.7...

Glboal Visceral Pain Therapeutics Pipeline Report 2016 - Research and Markets

Research and Markets has announced the addition of the "Visceral Pain - Pipeline Review, H2 2016" report to their offering.

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain Therapeutics, Inc. Class Action and Settlement Hearing - PTIE

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

The Life Sciences Report Examines How Analysts Keep Focus on DURECT's DUR-928

SAN FRANCISCO, CA--(Marketwired - October 07, 2016) - The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT Corp. (NASDAQ: DRRX) to Pain Therapeutics, has not changed the view...

The Life Sciences Report Examines How Analysts Keep Focus on DURECT's DUR-928

SAN FRANCISCO, CA--(Marketwired - October 07, 2016) - The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT Corp. (NASDAQ: DRRX) to Pain Therapeutics, has not changed the view...

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain Therapeutics, Inc. Class Action and Settlement Hearing - PTIE

IN THE UNITED STATES DISTRICT COURT

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Pain Therapeutics is developing a new generation of opioid painkillers.Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four opioid painkillers in Phase II clinical...

See More

Support & Resistance

2nd Resistance Point 0.65
1st Resistance Point 0.63
Last Price 0.58
1st Support Level 0.58
2nd Support Level 0.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.